| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Epidemiology and Biostatistics (Drs. Andersen, Launer, Ott, Hoes, Breteler, and Hofman), Erasmus University Medical School and the Netherlands Institute of Health Sciences, and the Department of General Practice (Dr. Hoes), Erasmus University Medical School, Rotterdam, The Netherlands.
Supported by grants from the NESTOR program for research on the elderly (supported by the Netherlands Ministries of Health and Education), the Netherlands Heart Foundation, the Netherlands Prevention Fund, the European Community Concerted Action on the Epidemiology of Dementia (EURODEM), and the Municipality of Rotterdam.
Received November 16, 1994. Accepted in final form January 24, 1995.
Address correspondence and reprint requests to Dr Launer, Department of Epidemiology and Biostatistics, Erasmus University Medical School, Rotterdam, The Netherlands.
Based on reports that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for Alzheimer's disease (AD), we studied the cross-sectional relation between NSAID use and the risk for AD in a population-based study of disease and disability in older people. After controlling for age, education, gender, and use of benzodiazepines, we found a relative risk (RR) for AD of 0.38 (0.15 to 0.95) when comparing NSAID users (n equals 365) to NSAID non-users (n equals 5,893). To address confounding by indication or contraindication, we compared NSAID users with a subset of NSAID non-users who were using topical medication for ear, eye, or dermatologic conditions (n equals 365). In this comparison, the adjusted RR for AD was 0.54 (0.16 to 1.78). These findings are compatible with a possible protective effect of NSAIDs on the risk for AD.
This article has been cited by other articles:
|
|
 |
|
  L. Calderon-Garciduenas, A. Mora-Tiscareno, G. Gomez-Garza, M. D. C. Carrasco-Portugal, B. Perez-Guille, F. J. Flores-Murrieta, G. Perez-Guille, N. Osnaya, H. Juarez-Olguin, M. E. Monroy, et al. Effects of a Cyclooxygenase-2 Preferential Inhibitor in Young Healthy Dogs Exposed to Air Pollution: A Pilot Study Toxicol Pathol, August 1, 2009; 37(5): 644 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, and D. A. Bennett Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology Neurology, June 3, 2008; 70(23): 2219 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. M. de Craen, J. Gussekloo, B. Vrijsen, and R. G. J. Westendorp Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia Am. J. Epidemiol., January 15, 2005; 161(2): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Cervilla, M Prince, S Joels, S Lovestone, and A Mann Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1100 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Etminan, S. Gill, and A. Samii Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies BMJ, July 17, 2003; 327(7407): 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence Epidemiol. Rev., December 1, 2002; 24(2): 248 - 268. [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Prasad, W. C. Cole, and K. C. Prasad Risk Factors for Alzheimer's Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment J. Am. Coll. Nutr., December 1, 2002; 21(6): 506 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Zandi, J. C. Anthony, K. M. Hayden, K. Mehta, L. Mayer, and J. C.S. Breitner Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study Neurology, September 24, 2002; 59(6): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. in 't Veld, A. Ruitenberg, A. Hofman, L. J. Launer, C. M. van Duijn, T. Stijnen, M. M.B. Breteler, and B. H.C. Stricker Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease N. Engl. J. Med., November 22, 2001; 345(21): 1515 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Anthony, J. C. S. Breitner, P. P. Zandi, M. R. Meyer, I. Jurasova, M. C. Norton, and S. V. Stone Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County Study Neurology, June 13, 2000; 54(11): 2066 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Lipsky, P. Brooks, L. J. Crofford, R. DuBois, D. Graham, L. S. Simon, L. B. A. van de Putte, and S. B. Abramson Unresolved Issues in the Role of Cyclooxygenase-2 in Normal Physiologic Processes and Disease Arch Intern Med, April 10, 2000; 160(7): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Aisen, K. L. Davis, J. D. Berg, K. Schafer, K. Campbell, R. G. Thomas, M. F. Weiner, M. R. Farlow, M. Sano, M. Grundman, et al. A randomized controlled trial of prednisone in Alzheimer's disease Neurology, February 8, 2000; 54(3): 588 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Nourhashemi, S. Gillette-Guyonnet, S. Andrieu, A. Ghisolfi, P. J. Ousset, H. Grandjean, A. Grand, J. Pous, B. Vellas, and J.-L. Albarede Alzheimer disease: protective factors1 Am. J. Clinical Nutrition, February 1, 2000; 71(2): 643s - 649s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Cummings and D. V. Jeste Alzheimer's Disease and Its Management in the Year 2010 Psychiatr Serv, September 1, 1999; 50(9): 1173 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Rogers, L. M. Leiter, J. McPhee, C. M. Cahill, S.-S. Zhan, H. Potter, and L. N. G. Nilsson Translation of the Alzheimer Amyloid Precursor Protein mRNA Is Up-regulated by Interleukin-1 through 5'-Untranslated Region Sequences J. Biol. Chem., March 5, 1999; 274(10): 6421 - 6431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Felician and T. A. Sandson The Neurobiology and Pharmacotherapy of Alzheimer's Disease J Neuropsychiatry Clin Neurosci, February 1, 1999; 11(1): 19 - 31. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. N. Dubois, S. B. Abramson, L. Crofford, R. A. Gupta, L. S. Simon, L. B. A. van de putte, and P. E. Lipsky Cyclooxygenase in biology and disease FASEB J, September 1, 1998; 12(12): 1063 - 1073. [Abstract] [Full Text]
|
|
|
|
|
|
J. V Bowler, D. G Munoz, H. Merskey, and V. Hachinski Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, January 1, 1998; 64(1): 18 - 24. [Abstract] [Full Text]
|
|
|
|
|
|
W. L. Smith, R. M. Garavito, and D. L. DeWitt Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and -2 J. Biol. Chem., December 27, 1996; 271(52): 33157 - 33160. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
